Molecular Oncology
Volume 2, Issue 1 , Pages 102-111 , June 2008

Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy

  • Laura M. Vargas-Roig

      Affiliations

    • Institute of Medicine and Experimental Biology of Cuyo, Regional Center for Scientific and Technological Research, National Research Council of Argentine, Mendoza 5500, Argentina
    • Corresponding Author InformationCorresponding author. Institute of Medicine and Experimental Biology of Cuyo (IMBECU), CRICYT, CC 855, Mendoza 5500, Argentina. Tel.: +54 261 524 4152; Fax: +54 261 524 4001.
    • ,
  • F. Darío Cuello-Carrión

      Affiliations

    • Institute of Medicine and Experimental Biology of Cuyo, Regional Center for Scientific and Technological Research, National Research Council of Argentine, Mendoza 5500, Argentina
    • ,
  • Nicolás Fernández-Escobar

      Affiliations

    • Institute of Medicine and Experimental Biology of Cuyo, Regional Center for Scientific and Technological Research, National Research Council of Argentine, Mendoza 5500, Argentina
    • ,
  • Pedro Daguerre

      Affiliations

    • Lagomaggiore Hospital, Mendoza 5500, Argentina
    • ,
  • Marcela Leuzzi

      Affiliations

    • Lagomaggiore Hospital, Mendoza 5500, Argentina
    • ,
  • Jorge Ibarra

      Affiliations

    • Lagomaggiore Hospital, Mendoza 5500, Argentina
    • ,
  • Francisco E. Gago

      Affiliations

    • Medical School, National University of Cuyo, Mendoza 5500, Argentina
    • ,
  • Silvina B. Nadin

      Affiliations

    • Institute of Medicine and Experimental Biology of Cuyo, Regional Center for Scientific and Technological Research, National Research Council of Argentine, Mendoza 5500, Argentina
    • ,
  • Daniel R. Ciocca

      Affiliations

    • Institute of Medicine and Experimental Biology of Cuyo, Regional Center for Scientific and Technological Research, National Research Council of Argentine, Mendoza 5500, Argentina

Received 9 October 2007 ,Revised 8 January 2008 ,Accepted 8 January 2008.

References 

  1. Apte SS, Mattei M-G, Olsen BR. Mapping of the human Bax gene to chromosome 19q13.3–q13.4 and isolation of a novel alternatively spliced transcript Bad. Genomics. 1995;26:592–594
  2. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res. 1998;4:2331–2336
  3. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin. Cancer Res. 2000;6:2751–2758
  4. Cheng EH-Y, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 1997;278:1966–1968
  5. Ciocca DR, Elledge R. Molecular markers for predicting the response to tamoxifen in breast cancer patients. Endocrine. 2000;13:1–10
  6. Cuello-Carrión FD, Ciocca DR. Improved detection of apoptotic cells using a modified in situ TUNEL technique. J. Histochem. Cytochem. 1999;47:1–3
  7. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr. Relat. Cancer. 1999;6:61–68
  8. Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int. J. Cancer (Pred. Oncol.). 1999;84:580–586
  9. Deng X, Gao F, May F. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood. 2003;102:3179–3185
  10. Doglioni C, Deis Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status. Virchows Arch. 1994;424:47–51
  11. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat. 1994;32:39–47
  12. Elledge RM, Green S, Howes L, Clark G, Berardo M, Allred DC, et al Bcl-2, p53, and response to tamoxifen in ER-positive metastatic breast cancer: a Southwest Oncology Group study. J. Clin. Oncol. 1997;15:1916–1922
  13. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat. 1998;48:107–116
  14. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 1998;16:107–114
  15. Fanelli MA, Cuello-Carrión FD, Dekker J, Schoemaker J, Ciocca DR. Serological detection of heat shock protein hsp27 in normal and breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 1998;7:791–795
  16. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Mauri FA, Boracchi P, et al Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1995;1:189–198
  17. Hoetelmans R, van Slooten HJ, Keijzer R, Erkeland S, van de Velde CJ, Dierendonck JH. Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells. Cell Death Differ. 2000;7:384–392
  18. Huang DC, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 1997;16:4628–4638
  19. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 2000;6:50–56
  20. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994;73:2013–2026
  21. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, et al. Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinomas. Cancer Res. 1995;55:4471–4478
  22. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin. Cancer Res. 1997;3:199–208
  23. Lee K-H, Im S-A, Oh D-Y, Lee S-H, Chie EK, Han W, et al Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by placlitaxel as adjuvant chemotherapy. BMC Cancer. 2007;7:63
  24. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 1997;3:593–600
  25. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Hoffman B, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:1799–1805
  26. Neri A, Marrelli D, Roviello F, DeMarco G, Mariani F, DeStefano A, et al. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res. Treat. 2006;99:77–83
  27. Nishita M, Inoue S, Tsuda M, Tateda C, Miyashita T. Nuclear translocation and increased expression of Bax and disturbance in cell cycle progression without prominent apoptosis induced by hyperthermia. Exper. Cell Res. 1998;244:357–366
  28. Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK, et al. Can patients’ likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?. Breast Cancer Res. Treat. 2004;86:181–189
  29. Ohmori T, Podack ER, Nishio K. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 1993;192:30–36
  30. Parton M, Krajewski S, Smith I, Krajewska M, Archer C, Naito M, et al. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin. Cancer Res. 2002;8:2100–2108
  31. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, et al Expression of BAG-1 and BCL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest. 2004;22:248–256
  32. Shinoura N, Yoshida Y, Nishimura M, Muramatsu Y, Asai A, Kirino T, et al. Expression level of Bcl-2 determines anti- or pro-apoptotic function. Cancer Res. 1999;59:4119–4128
  33. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 1994;86:499–504
  34. Sjöström J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmström P, et al The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 2002;8:811–816
  35. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. U.S.A. 1986;83:5214–5218
  36. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer (Pred. Oncol.). 1998;79:468–475
  37. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer (Pred. Oncol.). 1999;84:129–134
  38. Wang ZH, Ding MX, Chew-Cheng SB, Yun JP, Chew EC. Bcl-2 and Bax proteins are nuclear matrix associated proteins. Anticancer Res. 1999;19:5445–5450

PII: S1574-7891(08)00005-7

doi: 10.1016/j.molonc.2008.01.004

Molecular Oncology
Volume 2, Issue 1 , Pages 102-111 , June 2008

Article Tools

* Image Usage & Resolution